Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials

The term ‘osteoporosis care gap’ refers to the suboptimal therapeutic approach of individuals at high fracture risk that do not receive treatment either because they elude diagnosis as high-risk patients or because they are skeptical towards medication [1,2]. Several lines of evidence consider skepticism against medication as part of the communication gap between patients and health-providers that fail to address patient concerns, beliefs, preferences, or misconceptions [3–6]. As a result, patients with osteoporosis and high fracture risk that would benefit from anti-osteoporotic medication decid e not to initiate treatment or are not compliant with their medication or discontinue it earlier than advised [7,8].
Source: Maturitas - Category: Primary Care Authors: Tags: Review article Source Type: research